These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36653470)

  • 1. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
    Gong X; Karchin R
    Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
    Pérez-Núñez I; Rozalén C; Palomeque JÁ; Sangrador I; Dalmau M; Comerma L; Hernández-Prat A; Casadevall D; Menendez S; Liu DD; Shen M; Berenguer J; Ruiz IR; Peña R; Montañés JC; Albà MM; Bonnin S; Ponomarenko J; Gomis RR; Cejalvo JM; Servitja S; Marzese DM; Morey L; Voorwerk L; Arribas J; Bermejo B; Kok M; Pusztai L; Kang Y; Albanell J; Celià-Terrassa T
    Nat Cancer; 2022 Mar; 3(3):355-370. PubMed ID: 35301507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
    de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
    Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
    Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
    Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
    Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients.
    Shen HY; Xu JL; Zhu Z; Xu HP; Liang MX; Xu D; Chen WQ; Tang JH; Fang Z; Zhang J
    Neoplasia; 2023 Nov; 45():100942. PubMed ID: 37839160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade.
    Sahni S; Wang B; Wu D; Dhruba SR; Nagy M; Patkar S; Ferreira I; Day CP; Wang K; Ruppin E
    Nat Commun; 2024 Oct; 15(1):8867. PubMed ID: 39402030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade.
    Mei J; Cai Y; Xu R; Li Q; Chu J; Luo Z; Sun Y; Shi Y; Xu J; Li D; Liang S; Jiang Y; Liu J; Qian Z; Zhou J; Wan M; Yang Y; Zhu Y; Zhang Y; Yin Y
    Cancer Commun (Lond); 2024 May; 44(5):554-575. PubMed ID: 38507505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
    Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
    Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
    Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
    Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
    J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance.
    Thier B; Paschen A
    Cell Stress; 2021 Jan; 5(2):26-28. PubMed ID: 33554047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
    Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
    J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy.
    Dong Y; Gao Q; Chen Y; Zhang Z; Du Y; Liu Y; Zhang G; Li S; Wang G; Chen X; Liu H; Han L; Ye Y
    Nat Commun; 2023 May; 14(1):2540. PubMed ID: 37137884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response.
    Chen R; Zhang H; Wu W; Li S; Wang Z; Dai Z; Liu Z; Zhang J; Luo P; Xia Z; Cheng Q
    Front Immunol; 2022; 13():833792. PubMed ID: 35418980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity.
    Zheng M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
    Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
    Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.